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RESEARCH REPORT
Left ventricular hypertrophy and risk of fatal and non-fatal
stroke. EUROSTROKE: a collaborative study among
research centres in Europe
M L Bots, Y Nikitin, J T Salonen, P C Elwood, S Malyutina, A Freire de Concalves,
J Sivenius, A Di Carlo, P Lagiou, J Tuomilehto, P J Koudstaal, D E Grobbee
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Background: This study investigated the association between electrocardiographically assessed left
ventricular hypertrophy (LVH) and fatal, non-fatal, haemorrhagic and ischaemic stroke in four European
cohorts participating in EUROSTROKE.
Methods: EUROSTROKE is a collaborative project among ongoing European cohort studies to investi-
gate differences in incidence of, and risk factors for, stroke between countries. EUROSTROKE is
designed as a nested case-control study. For each stroke case, two controls were sampled. Strokes
were classified according to MONICA criteria or reviewed by a panel of four neurologists. LVH was
assessed according to the Minnesota code or the automated diagnostic MEANS classification system.
For this analysis, data on LVH and stroke were available from cohorts in Cardiff (84 cases/200 con-
trols), Kuopio (60/116), Rotterdam (114/334), and Novosibirsk (62/168). Results are adjusted for
age and sex.
Results: LVH was associated with a twofold increased risk of stroke (odds ratio 2.1 (95% CI 1.3 to
3.5). The risk was particularly pronounced for fatal stroke (4.0 (95% CI 2.1 to 7.9)), whereas the risk
was non-significantly increased for non-fatal stroke (1.5 (95% CI 0.8 to 2.7)). The increased risk was
more pronounced in smokers: for total stroke 3.5 (95% CI 1.5 to 8.1) versus 1.6 (95% CI 0.8 to 3.1)
in non-smokers. Adjustment for systolic blood pressure and body mass index attenuated the
associations. LVH was not preferentially associated with a particular type of stroke, although the
association with cerebral infarction was stronger.
Conclusion: This analysis of the EUROSTROKE project indicates that LVH assessed by electrocardio-
gram is a predictor of stroke. The association seems to be stronger for fatal stroke than for non-fatal
stroke and is more pronounced in smokers.
It has been convincingly shown that subjects with leftventricular hypertrophy (LVH) are at a considerableincreased risk of coronary morbidity and mortality both
among the general population1 2 and among hypertensive
patients.3 4 Also, in subjects with recent cerebral ischaemia,
LVH is a powerful predictor of future cardiac events.5 Further-
more, evidence is emerging that regression of LVHmay reduce
the risk of cardiovascular disease,6 which emphasises the
importance of LVH assessment in risk profiling.7
In most studies on the association of LVH with future
disease, cardiovascular disease included a variety of clinical
manifestations, such as angina pectoris, myocardial infarc-
tion, congestive heart failure, sudden cardiac death, and occa-
sionally stroke. A number of studies, however, have specifically
investigated the association of LVH with stroke.8–14 These stud-
ies were either restricted to fatal stroke only, or no distinction
between fatal and non-fatal stroke was made. Furthermore,
differences in associations with various types of stroke have
not been evaluated.
We evaluated the association between electrocardiographi-
cally assessed LVH and fatal, non-fatal, haemorrhagic and
ischaemic stroke by combining data from four European
cohorts participating in EUROSTROKE.
METHODS
The rationale and design of EUROSTROKE have been
described in detail elsewhere.15 In short, EUROSTROKE is a
collaborative study among European research centres to
investigate (1) the variation in incidence of fatal and non-fatal
ischaemic and haemorrhagic stroke among populations in
different European countries; (2) whether the observed
differences in stroke incidence across countries can be
explained by differences in prevalence of established cardio-
vascular risk factors; (3) the relative importance of smoking
and some selected dietary factors (potassium intake, alcohol
consumption), haemostatic disturbances (fibrinogen) and
comorbidity (rheumatic heart disease, atrial fibrillation) com-
pared with established risk factors as determinants of the
occurrence of ischaemic and haemorrhagic stroke. The
EUROSTROKE database is drawn from ongoing European
population-based prospective follow up studies (cohorts) and is
designed as a case-control study nested within these ongoing
studies. For each stroke case, two controls were sampled. Con-
trols were matched on day of baseline examination only. Apart
from its objectives, the EUROSTROKE database allows for
aetiological analyses looking into various risk factors for
stroke. EUROSTROKE formally started on 1 January 1994. At
present, data from four cohorts were available for analysis.
EUROSTROKE case review board
Stroke was defined as a clinical event of rapid onset consisting
of neurological deficit lastingmore than 24 hours unless death
supervenes, or if is lasts less than 24 hours, an appropriate
lesion to explain the deficit is seen in a brain image. The event
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could not be directly caused by trauma to the brain, tumour, or
infection. This definition included subjects presenting with
signs and symptoms suggestive of a subarachnoid haemor-
rhage, an intracerebral haemorrhage, ischaemic cerebral
infarction, and subjects with a transient ischaemic attack,
provided neuroimaging has been performed. A case reviewing
panel consisting of four neurologists classified stroke events
occurring in EUROSTROKE based on the information that
was obtainable such as patients history, results from a lumbar
puncture, computed tomography or magnetic resonance
images, findings from a necropsy report. Final codes from
existing and operating registries, such as, for example, the
FINMONICA registry were not reviewed separately, but used
as coded. Based on the information present, the neurologist
classified the event into first and recurrent stroke, and into
subarachnoid haemorrhage, intracranial haemorrhage, intra-
cerebral infarction, or unspecified stroke. In addition, the cer-
tainty of the diagnosis was assessed in definite, probable, pos-
sible, and no stroke. Events were classified by two
neurologists; in case of disagreement a third arbitrated.
This analysis is restricted to definite and probable events.
An incident stroke was considered to have occurred when (1)
the event had led to a hospitalisation and the hospital
discharge record indicated a diagnosis of a new stroke. The
clinical diagnosis was based on signs and symptoms, and neu-
roimaging investigations during hospital stay (definite
stroke); or (2) in case of no hospitalisation, signs and
symptoms associated with the event obtained from the
general practitioner’s records were highly suggestive of a
stroke according to the neurologists (probable stroke) or (3) in
case of out hospital death, when the general practitioner
reported that the cause of death was a cerebrovascular
accident and a cardiac cause was judged by the general prac-
titioner to be highly unlikely (probable stroke).
Finland
The Finnish contribution to EUROSTROKE comes from the
Kuopio Ischemic Heart Disease Risk Factor study, which is a
population-based prospective cohort study comprised of an
age stratified random sample of 2682 men aged 42, 48, 54 and
60 years. The baseline examination was performed between
1984 and 1989.16 Fatal and non-fatal stroke cases were
collected through the national mortality statistics and the
FINMONICA stroke registries. Stroke was defined according
to FINMONICA criteria and definitions.17 Case ascertainment
from the baseline examination to 1 January 1993 revealed 74
stroke cases. Controls subjects (n=148) were randomly drawn
from the cohort that remained free from stroke during follow
up.
The Netherlands
The Dutch contribution to EUROSTROKE comes from the
Rotterdam Study, which is a population-based prospective fol-
low up study among 7983 subjects, aged 55 years or over, liv-
ing in the suburb of Ommoord in Rotterdam, the
Netherlands.18 Baseline data were collected from March 1990
to July 1993. In the Rotterdam Study, information on incident
fatal and non-fatal events is obtained from the general practi-
tioners (GPs) working in the study district of Ommoord as
described earlier.19 In short, the GPs involved report all possi-
ble cases of stroke to the Rotterdam research centre. Events
are presented in coded information following the Inter-
national Classification of Primary Care (ICPC).20 With respect
to the vital status of the participants, information is obtained
at regular intervals from the municipal authorities in Rotter-
dam and also death of a participant is reported. When an
event or death has been reported, additional information is
obtained by interviewing the GP and scrutinising information
from hospital discharge records in case of admittance or refer-
ral. All suspected cerebrovascular events reported by the GPs
were submitted for review to the EUROSTROKE case review
board. From baseline to December 1994, 192 stroke cases were
identified and submitted for review and a total of 384 control
subjects were drawn from the remainder of the cohort that
remained free from stroke during follow up. Altogether 157
events were classified as definite or probable strokes.
Russia
The Russian contribution to EUROSTROKE originates from
studies performed in the Octyabrsky, the Kirovsky and Lenin-
sky districts of Novosibirsk, Siberia. The Novosibirsk cohort is
based on three population-based surveys, which were
conducted between 1984 and 1989 as part of the WHO
MONICA project.21 The Novosibirsk cohort comprises 9006
men and women aged 25 to 64 years. Stroke cases were
collected through a specifically developed stroke registry, aim-
ing to identify fatal and non-fatal hospitalised and non-
hospitalised stroke patients.22 23 Stroke events were defined
according to MONICA criteria and definitions.24 From baseline
to December 1995, a total of 100 stroke cases had been identi-
fied and 200 control subjects were drawn from the database.
Finally, 79 subjects proved to be true strokes.
United Kingdom
The British contribution to EUROSTROKE comes from the
Caerphilly Heart Disease study in Wales, United Kingdom, in
which 2512 men, aged 45 to 59 years are participating.25 Base-
line examinations took place from 1979 to 1983. Follow up
examinations were performed from 1984 to 1988 (phase II)
and from 1989 to 1993 (phase III). Stroke events were
registered through national mortality statistics, hospital
discharge records, self report and family report. Of the
registered events, additional information on signs and symp-
toms, on neuroimaging, necropsy and a copy of the discharge
records were collected. When complete, stroke cases were
submitted for review to the EUROSTROKE case review board
as descried earlier. Recently, 100 stroke events had been
submitted for review and 200 controls subjects had been
drawn from the remaining cohort. Eighty four stroke cases
were classified as definite/probable stroke by the EURO-
STROKE case review board.
Cardiovascular risk factors
Because EUROSTROKE is based on 10 ongoing cohort studies,
information on cardiovascular risk factors in each of the par-
ticipating centres was already collected before the formal start
of the EUROSTROKE project. Whenever possible, an exhaus-
tive attempt was made to further harmonise the collected
information to make comparison across studies possible.
Nevertheless, any baseline measurements could not be further
standardised beyond the attempts done in each individual
study.
In each of the centres information on smoking, alcohol
consumption, and medical history was obtained by question-
naire. The subject’s smoking behaviour was categorised into
current, former or never. Alcohol consumption was catego-
rised into current drinkers and non-current drinkers (former
and never). In addition, an estimate of grams of alcohol per
day was obtained. Presence of diabetes mellitus was generally
based on the question “Do you suffer from diabetes mellitus?”.
In the Rotterdam study diabetes mellitus was considered
present when subjects used blood sugar lowering drugs,
Key points
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whereas in the Novosibirsk study presence of diabetes mellitus
was not evaluated for the entire cohort. Information on a his-
tory of stroke was obtained by direct questioning at baseline
“Did you ever suffer from a stroke?”. A similar approach was
taken for myocardial infarction. Presence of angina pectoris
was based on either the cardiovascular Rose questionnaire or
direct questioning.
In general, systolic and diastolic blood pressure were
measured twice at one occasion in sitting position. In Cardiff,
only one blood pressure measurement was performed. Height
and weight were measured and body mass index (kg/m2) was
calculated. In all four centres an electrocardiogram was made.
In Cardiff, Kuopio and Novosibirsk, LVH was assessed accord-
ing to the Minnesota classification system (codes 3.1, 3.3,
3.4).26 In Rotterdam, an automated diagnostic classification
system of the Modular Electrocardiogram Analysis System
(MEANS) was used in which LVH diagnosis was assessed on
the parameters voltage, shape and repolarisation, as detailed
elsewhere.27 28 Apart from Rotterdam, a fasting blood sample
was taken for determination of serum lipids (total cholesterol,
HDL cholesterol). For the present analysis hypertension was
defined as a systolic blood pressure of 160 mm Hg or over, or a
diastolic blood pressure of 95 mm Hg or over, or current use of
blood pressure lowering drugs.
Data analysis
Complete data on both stroke and LVH were available for Car-
diff (84 cases/200 controls), Kuopio (60 cases/ 116 controls),
Rotterdam (114 cases/334 controls), and Novosibirsk (62
cases/168 controls).
The analyses were first performed for each centre sepa-
rately. To identify potential confounding variables, cardiovas-
cular risk factors that were related to stroke were examined
using logistic regression models and to LVH using logistic
regression models. Factors that were related to both stroke
and LVH (p<0.10), and that were not assumed to be in the
causal pathway of LVH leading to stroke were considered con-
founding variables. Systolic blood pressure, diastolic blood
pressure, body mass index, current smoking, and diabetes
mellitus were evaluated as potential confounders. LVH as pre-
dictor of stroke was studied as a dichotomeous variable using
logistic regression analysis. Initially adjustments were made
for age and sex, and subsequently for potential confounding
cardiovascular risk factors.
An interaction term (LVH × centre) was used to study
whether the association between LVH and stroke differed
across the four centres (heterogeneity). Interaction term (LVH
× sex) was used to evaluate whether the association differed
betweenmen and women. Similar analyses were performed in
strata of smoking and hypertension. Results are presented as
odds ratios,with their corresponding 95% confidence intervals
(95% CI). Separate analyses were performed for total stroke,
first ever stroke, fatal stroke (death within 28 days after
onset), non-fatal stroke, and for haemorrhagic stroke and cer-
ebral infarction.
In the analysis in which a history of diabetes mellitus was
used, analyses were initially performed excluding data from
Novosibirsk, because in this centre such data were not
available. Additional analyses were performed in which
history of diabetes was imputed for the Novosibirsk centre.
The imputation was based on the prevalence observed in Car-
diff and Kuopio combined, an estimate comparable to what
has been reported for Novosibirsk area.13 A dummy variable
(yes/no) for the imputation was added to the model. As the
magnitude of findings did not differ between the two
approaches only the latter is presented. The analyses have
been performed using STATA version 4.0.
RESULTS
General characteristics of the study populations are given in
table 1. Characteristics of the stroke events are presented in
table 2. Of all strokes, 73% had been hospitalised. Neuroimag-
ing (CT/MRI) had been performed in 55% of the cases. Among
the fatal strokes, 26.2% were a haemorrhagic, 33.8% a cerebral
infarctions and 40.0% could not be specified with the available
information. The corresponding figures for non-fatal stroke
were 9.6%, 80.4% and 10.0%, respectively. In analyses in which
Table 1 General characteristics of the study population
Characteristic Cardiff, UK Kuopio, FIN Rotterdam, NL Novosibirsk, RUS All
Case/control 84/200 60/116 114/334 62/168 320/808
Age at entry (y) 57.6 (5.9) 55.2 (4.1) 74.0 (10.1) 51.6 (9.1) 62.9 (13.0)
Female (%) * * 64.5 40.1 37.2
Systolic pressure (mm Hg) 146 (22) 132 (18) 144 (24) 145 (26) 143 (24)
Diastolic pressure (mm Hg) 86.2 (12.7) 88.7 (10.4) 74.2 (12.8) 93.4 (14.1) 83.6 (15.6)
Total cholesterol (mmol/l) 5.8 (1.2) 6.1 (1.2) 6.6 (1.3) 5.8 (1.3) 6.2 (1.3)
HDL cholesterol (mmol/l) 1.05 (0.33) 1.26 (0.28) 1.34 (0.37) 1.27 (0.38) 1.26 (0.37)
Current smoking (%) 47.1 27.9 22.7 35.1 31.2
Body mass index (kg/m2) 26.6 (3.6) 26.9 (3.4) 26.1 (3.7) 28.3 (5.3) 26.9 (4.2)
Diabetes mellitus (%) 4.2 6.3 9.0 NA† 7.5
LVH (%) 3.5 4.0 7.4 8.3 6.1
Values are unadjusted proportions or means with standard deviations in parentheses. *Only men participated in the study; †NA=not assessed.
Table 2 Stroke characteristics in each of the participating centres
Characteristic Cardiff, UK Kuopio, FIN Rotterdam, NL Novosibirsk, RUS All
Hospitalised (%) 77 90 69 69 75
CT (%) 48 88 72 5 55
First event 74 53 96 61 284
Total stroke 84 60 114 62 320
Fatal 24 11 26 19 80
Non-fatal 60 49 88 43 240
Haemorrhagic 11 13 11 9 44
Ischaemic 57 44 74 45 220
Unspecified 16 3 29 8 56
Values are absolute numbers.
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information from all centres was combined, age, male sex,
systolic blood pressure, diastolic blood pressure, hypertension,
current smoking, and history of diabetes mellitus were
positively, and significantly (p<0.05) related to stroke.
Significant associations with LVH were found for age, systolic
blood pressure, diastolic blood pressure and hypertension.
Interaction terms indicated no difference in associations
between centres (p=0.49) and between men and women
(p=0.92).
The association of LVH to stroke for each centre is given in
figure 1. In all centres LVH was positively related to the risk of
stroke. The centre specific analyses did not always reach the
level of statistical significance. The wide confidence interval
reflects the limited number of subjects with LVH in each cen-
tre. There was no evidence for heterogeneity.
Table 3 describes the association between LVH and risk of
stroke for all centres combined. LVH was associated with a
twofold increased risk of stroke (odds ratio 2.13 (95% CI 1.29
to 3.50). Results were similar for first ever stroke. The
increased risk seemed to be stronger for fatal stroke than for
non-fatal stroke (table 3). When differences in systolic blood
pressure and body mass index were taken into account, the
magnitude of the associations between LVH and all types of
stroke was attenuated. Additional adjustment for hyper-
tension, smoking and diabetes mellitus did not materially
affect the magnitude, direction and significance of the
findings (table 3).
Subjects with LVH had a non-significant increased risk of
cerebral infarction compared with those without LVH (age
and sex adjusted odds ratio 1.68 (95% CI 0.92 to 3.04),
p=0.09). The association was more pronounced for fatal than
for non-fatal cerebral infarction: odds ratios 3.66 (95% CI 1.19
to 11.2) and 1.44 (95% CI 0.75 to 2.78), respectively. No
significant association was found with haemorrhagic stroke
(age and sex adjusted odds ratio of 1.52 (95% CI 0.45 to 5.18),
p=0.50) or with fatal haemorrhagic stroke (odds ratio 1.03
(95% CI 0.13 to 7.90)) or non-fatal haemorrhagic stroke (odds
ratio 2.03 (95% CI 0.45 to 9.06)).
Stratified analyses among smokers and non-smokers
showed different tendencies in magnitude in the associations
of LVH with stroke (table 4). In smokers, LVH was associated
with a 3.47-fold (95% CI 1.49 to 8.09) increased risk of stroke,
whereas in non-smokers the risk was 1.61 (95% CI 0.84 to
3.12). The interaction term, however, did not reach statistical
significance (p=0.15).No differences in magnitude in associ-
ation of LVH to stroke was found for men and women nor for
hypertension and normotension.
DISCUSSION
This analysis of the EUROSTROKE project indicates that LVH
assessed by electrocardiogram is a predictor of stroke. The
association seemed to be stronger for fatal stroke than for
non-fatal stroke and may be restricted to smokers. Further-
more, no major differences were seen in the magnitude of the
association with haemorrhagic stroke and cerebral infarction,
if anything the relation with cerebral infarction was more
pronounced.
Several aspects of this study should be considered. Firstly,
we cannot be sure about the completeness of case ascertain-
ment in each study. The proportion of fatal cases across the
centres ranged between 19.3% in Kuopio and 30.6% in
Novosibirsk (table 2). Although it is likely that there are true
differences in case-fatality of stroke across these countries this
may indicate underrepresentation of non-fatal cases. If the
selection of non-fatal cases is associated with a lower
Figure 1 Left ventricular hypertrophy and risk of stroke, by centre.
Results are adjusted for age and sex, when appropriate.
Cardiff
Kuopio
Rotterdam
Novosibirsk
Pooled
Odds ratio (95% CI)
0 13121110987654321
Table 3 The association of left ventricular hypertrophy and risk of stroke
Model I Model II Model III Model IV
All strokes 2.13 (1.29 to 3.50) 1.72 (1.02 to 2.89) 1.62 (0.93 to 2.81) 1.62 (0.43 to 2.81)
First ever 2.13 (1.27 to 3.56) 1.70 (0.99 to 2.92) 1.65 (0.95 to 2.87) 1.57 (0.89 to 2.78)
Fatal 4.02 (2.05 to 7.89) 3.14 (1.55 to 6.36) 2.93 (1.37 to 6.26) 2.76 (1.25 to 6.11)
Non-fatal 1.52 (0.84 to 2.76) 1.19 (0.64 to 2.23) 1.19 (0.64 to 2.24) 1.19 (0.63 to 2.28)
Haemorrhagic 1.52 (0.45 to 5.10) 1.08 (0.30 to 3.86) 1.12 (0.31 to 4.10) 1.10 (0.29 to 4.19)
Cerebral infarction 1.67 (0.92 to 3.04) 1.34 (0.72 to 2.53) 1.34 (0.72 to 2.53) 1.35 (0.72 to 2.59)
Cerebral infarction* 2.21 (1.32 to 3.69) 1.82 (1.07 to 3.11) 1.70 (0.98 to 2.96) 1.74 (0.99 to 3.06)
Odds ratios relative to subjects without LVH, with 95% confidence intervals. *Ischaemic, including subjects with unspecified stroke. Model I: Adjusted for
age and sex; Model II: Adjusted for age, sex and systolic blood pressure; Model III: Adjusted for age, sex, systolic blood pressure, and body mass index;
Model IV: Adjusted for age, sex, systolic blood pressure, body mass index, diastolic blood pressure, hypertension, current smoking and diabetes mellitus.
Table 4 Stratified analyses of the association of LVH with stroke and cerebral infarction
Cases/controls Stroke Cases/controls Cerebral infarction
Smoking (yes) 131/245 3.47 (1.49 to 8.08) 91/245 1.91 (0.68 to 5.40)
Smoking (no) 185/567 1.61 (0.84 to 3.11) 126/567 1.71 (0.80 to 3.64)
Hypertension (yes) 181/317 1.89 (1.00 to 3.58) 117/317 1.75 (0.82 to 3.73)
Hypertension (no) 139/501 2.07 (0.91 to 4.71) 103/501 1.46 (0.52 to 4.11)
Men 230/543 2.10 (1.12 to 3.88) 162/543 1.70 (0.82 to 3.50)
Women 90/275 2.23 (0.95 to 5.22) 58/275 1.84 (0.62 to 5.44)
Results are adjusted for ages and for sex, when appropriate.
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prevalence of the exposure of interest (LVH), it may bias a true
positive association towards a reduced odds ratio or a null
finding.We have nomeans to evaluate whether this indeed did
take place. Secondly, the association with fatal stroke may be
biased towards a positive finding when in the assessment a
large proportion of the stroke cases was misclassified—that is,
had died from coronary heart disease rather than from stroke.
Given the diagnostic procedures in the participating centres
this is unlikely to have happened. Thirdly, it has been well
established that the sensitivity of the ECG to detect LVH is
limited. Data from the Framingham Heart Study indicated a
sensitivity of 6.9% and a specificity of 98.8% compared with
echocardiography as gold standard.29 The ultimate conse-
quence of this notion is that most probably the reported asso-
ciations under study are an underestimation of the “true”
association; as misclassification occurred in both cases and
controls, most probably in a random fashion. Alternatively, a
recent paper indicated that ECG-LVH and LVH assessed by
echocardiography carry to some extent different prognostic
information.30 Finally, we acknowledge that the diagnoses of
LVH has been made using different approaches. We used
whatever approach had been taken in the individual cohort.
Some may have a stronger prognostic implication.30 However,
in all cohorts, ECG-LVH was related to risk of stroke without
showing differences in associations across the cohorts (fig 1).
Strengths of this study are the fairly large number of well
diagnosed and classified events for both men and women,
presence of data on a large number of potential confounders,
a wide age range, and risk factors assessment before the
occurrence of the stroke event.
Several studies have evaluated the association between LVH
and stroke (table 5). Direct comparison between studies is
hampered by differences in population distribution, in
selection of population, in methods of assessing LVH, in stroke
distribution (fatal/non-fatal, type of stroke) and in adjust-
ment for several potential confounding variables. In general,
an increased stroke risk was found among subjects with LVH.
In reports of the Framingham Heart study, with different
samples from the populations and duration of follow up, LVH
was associated with a sixfold increased risk of stroke among
middle aged men and women 7 and with a 2.3-fold increased
risk in the elderly.8 Results from Dunn and coworkers in the
United Kingdom showed that among hypertensives the
relative contribution of LVH to death from stroke decreased
with age.3 In the Copenhagen City Heart Study in Denmark
weaker than in the Framingham Heart Study, associations
were found for men and no relation was seen for women
(table 5).9 Few studies, however, have distinguished between
fatal and non-fatal stroke. In a community-based cohort study
among 459 subjects aged 75 to 85 years, who were followed up
for 10 years, baseline LVH was associated with a threefold
increased risk of fatal stroke (p=0.07), whereas a non-
significant increased risk of non-fatal stroke was found (odds
ratio 1.1).11 The analyses were, however, based on a limited
number of fatal (n=15) and non-fatal (n=20) events. The
present EUROSTROKE analysis confirms the increased risk of
stroke associated with LVH. In addition, our findings point
towards a stronger association of LVH with fatal stroke than
with non-fatal stroke, a tendency observed for cerebral infarc-
tion only. In this analysis, the increased risk was more
pronounced in smokers than in non-smokers. As none of the
studies reported such a finding, future studies are needed to
confirm this potential effect modification of smoking in stroke
risk. It has not been clear by which mechanism smoking
increases the risk of stroke. This new finding that LVH may be
a condition required for stroke to occur in smokers may
suggest that the underlying mechanism is related to either
arrythmias31–33 or other cardiac events.
Several hypotheses have been given to explain why LVH
predisposes for coronary heart disease and death.6 Yet, the
mechanisms for stroke may be less clear. Firstly, LVH may be a
marker for presence of longstanding increased blood pressure
and as such it may reflect cardiovascular end-organ damage,
which in itself is associated with increased risk of stroke. Our
finding that when differences in blood pressure were taken
into account the association between LVH and stroke was
reduced, favours this view. Secondly, LVH has been implicated
as an important factor in triggering cardiac arrhythmias,31 32
which may increase the risk of stroke, in particular ischaemic
stroke.
Increased blood pressure has consistently been reported as
a major determinant of LVH.7 The increased stroke risk of LVH
Table 5 Overview of some population-based studies in which the association between LVH and stroke was studied
First author Subjects Age (y) FUP (y)
Number of
strokes
Stroke
type
Fatal
non-fatal
Prevalence
LVH (%) Main finding on risk Remarks
Dunn, 1990†3 1624 M 45–74 6.5 29 (any) NR Fatal 21.7 1.8 Age adjusted
1650 F 17 (any) 12.7 4.0 Age adjusted
Aronow, 1991†10 88 M 62 3.6 68 (any) CI Combined 14.7 2.10 (1.11 to 3.98)*
238 F
Wolf, 19918 2372 M 55–84 10 213 (first) NR Combined 3.5 M 2.32*
3362 F 259 (first) 2.9 F 2.34*
Kannel, 19927 2372 M 35–64 36 NR NR Combined 4.8 5.8*
3362 F 3.4 6.2*
Truelsen, 19949 3015 M 55–84 10 286 (first) NR Combined 20.6 M 1.32 (1.01 to 1.73)*
3501 F 188 (first) 11.3 F 1.00 (0.66 to 1.51)*
Kahn, 199611 459 75–85 10 35 NR 15 Fatal 9.2 3.03 (1.09 to 10.6)* Unadjusted
20 NF 1.1 Unadjusted
Feigin, 199813 237 cases 68 – 237 CI Combined 18.1% cases 1.77 (1.70 to 19.9)*
257 controls 2.1% controls
Tanne, 199814 9734 M >40 21 282 CI Fatal 1.87% 2.15 (1.12 to 4.12)*
Aronow 199912 2384 81 44 510 TE Combined – 2.8*
M=men, F=female, FUP=mean duration of follow up in years, NR=not reported, ICH=cerebral haemorrhage, CI=cerebral infarction, TE=thromboembolic.
*Adjusted for cardiovascular risk factors (full model); †subjects with hypertension only.
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among smokers further supports the large potential for
prevention of stroke by lowering of blood pressure and
discouraging starting and encouraging quitting smoking.
In conclusion, this analysis of the EUROSTROKE project
indicates that LVH assessed by electrocardiogram is a powerful
predictor of stroke. The association seems to be stronger for
fatal stroke than for non-fatal stroke and is more pronounced
in smokers.
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